预约演示
更新于：2025-03-04
Galantamine Hydrobromide
氢溴酸加兰他敏
更新于：2025-03-04
概要
基本信息
药物类型 小分子化药 |
别名 (-)-Galanthamine、Galantamine、Galantamine hydrobromide (JAN/USP) + [19] |
靶点 |
作用机制 AChE抑制剂(乙酰胆碱酯酶抑制剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 瑞典 (2000-11-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H22BrNO3 |
InChIKeyQORVDGQLPPAFRS-XPSHAMGMSA-N |
CAS号1953-04-4 |
关联
122
项与 氢溴酸加兰他敏 相关的临床试验TCTR20241215009
A Single-dose, Randomized, Open-label, Crossover Bioequivalence Study of Generic Galantamine 8 mg Capsule and Reference Product in Healthy Thai Volunteers under Fasting and Fed Conditions
ChiCTR2400094516
Study of Galantamine for the treatment of Alzheimer's disease based on real world
CTR20242087
氢溴酸加兰他敏口崩片（8mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 氢溴酸加兰他敏 相关的临床结果
登录后查看更多信息
100 项与 氢溴酸加兰他敏 相关的转化医学
登录后查看更多信息
100 项与 氢溴酸加兰他敏 相关的专利（医药）
登录后查看更多信息
4,946
项与 氢溴酸加兰他敏 相关的文献（医药）2025-03-01JOURNAL OF MOLECULAR STRUCTURE
Evaluation of isatin-1,3,5-triazine-benzylamine hybrids as multi-target directed ligands against Alzheimer's disease
作者: Razzaghi-Asl, Nima ; Tamaddon-Abibigloo, Yasaman ; Tuylu uKucukkilinc, Tuba ; Dastmalchi, Siavoush ; Shahbazi Mojarrad, Javid
In this study a new series of isatin-1,3,5-triazine-benzylamine hybrids (6a-k) were designed, synthesized and evaluated for in vitro anti-Alzheimer′s disease(AD) properties.These mols. were tested for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes inhibition and biometal chelation effect.Results revealed these mols. to be very potent AChE inhibitors with IC50 values in the range of 0.86-36.30nM.BChE inhibition potencies were also good and IC50 values for active compounds were from 0.66 to 3.88 μM.Mol. 6c had the highest activity against both enzymes and further studies showed that it kinetically inhibited AChE and BChE with non-competitive and competitive mechanisms, resp.This compound could effectively inhibit amyloid beta self/Cu2+ induced aggregation in 10μM.These compounds could significantly chelate to Cu2+ as an important biometal involved in AD andin silico simulations demonstrated that these mols. had key interactions with both ChE enzymes.It was concluded that these compounds had high potency to be used in future evaluations as anti-AD lead compounds
2025-03-01BIOSENSORS & BIOELECTRONICS
Innovative bioinspired hydrogel scaffolds enabling in-situ hybrid nanoflower integration for dual-mode acetylcholinesterase inhibitor profiling
Article
作者: Zhang, Xiaolong ; Yang, Limin ; Liu, Xingyi ; Wei, Dongsheng ; Liu, Zhen
This study introduces an innovative bioinspired hydrogel scaffold tailored to facilitate the in-situ integration of hybrid nanoflowers (HNFs) into the sensing interface, thereby establishing a versatile dual-mode platform for the sensitive profiling of acetylcholinesterase (AChE) inhibitors, a pivotal aspect in the pursuit of Alzheimer's disease therapeutics. Mimicking the tenacious anchoring of natural tree roots, our design employs magnetic bead imprinting with Strep-Tactin-coated magnetic beads (STMBs) to shape the hydrogel, which is then complemented by the integration of AChE-specific aptamers. This configuration creates a stable and biomimetic environment that nurtures HNF growth, thereby enhancing the binding integrity of HNFs with sensing interfaces. The platform's dual-mode detection capability, integrating both colorimetric and electrochemical sensing, is demonstrated through the effective evaluation of galantamine's inhibitory potency, with IC50 values that highlight its therapeutic potential. The hydrogel's exceptional reusability, maintaining over 95% of its initial activity after multiple uses, and its long-term stability, retaining 91% of its initial performance, further highlight its practicality and cost-effectiveness. In summary, this bioinspired hydrogel scaffold offers a novel, efficient, and dependable biosensing strategy for HNF-based biosensors, showing great potential for broad applications in medical diagnostics and advanced biosensing technologies.
2025-03-01TALANTA
Sensitive and eco-friendly voltammetric detection of galantamine using a screen-printed sensor with a functional boron-doped diamond electrode
Article
作者: Gawor, Andrzej ; Bulska, Ewa ; Dubenska, Liliya ; Panas, Krystyna ; Vojs, Marian ; Marton, Marian ; Matvieiev, Oleksandr ; Dushna, Olha
The presented study focused on developing and optimizing a modern electroanalytical platform for the direct quantitative determination of galantamine. This work used different voltammetric methods to use a screen-printed sensor with a working boron-doped diamond electrode (SP/BDDE). Beneficial analytical performance for detecting galantamine was achieved in a Britton-Robinson buffer with pH 3.0. The oxidation peaks at 0.92 V and 1.20 V were followed for electrochemical quantification of galantamine. High-resolution mass spectrometry was used for the first time to analyze the products of preparative electrolysis, and a mechanism for the electrochemical oxidation of galantamine was proposed, which describes the demethylation of galantamine and the further oxidation of the hydroxyl group to a ketone group in the galantamine molecule. Coupled with the optimized parameters of differential pulse voltammetry and square-wave voltammetry on the SP/BDDE detected galantamine in two linear ranges (the first range was from 1.22 μM to 10 μM; the second range was from 10 μM to 200 μM), providing the limit of detection and limit of quantification on a micromolar level (0.50 μM and 1.48 μM, respectively). Amperometry and chronoamperometry were employed to develop a rapid detection method for galantamine. In this approach, galantamine can be detected at a level of 1.08 μM (amperometry at the second peak). The selectivity of the optimized amperometric methods was found to be excellent in the presence of ten times higher concentrations of certain interferences. The practical applicability of the SP/BDDE for detecting galantamine was demonstrated through the analysis of pharmaceutical products and human urine samples. The proposed procedure fully complies with the latest requirements of green analytical chemistry.
92
项与 氢溴酸加兰他敏 相关的新闻（医药）2025-02-20
2025-02-13
抗体药物偶联物临床结果临床2期申请上市
100 项与 氢溴酸加兰他敏 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 美国 | 2001-02-28 | |
| 痴呆 | 美国 | 2001-02-28 | |
| 阿尔茨海默病引起的痴呆症 | 瑞典 | 2000-11-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 精神分裂症 | 临床3期 | - | 2003-03-01 | |
| 路易体病 | 临床3期 | 美国 | 2002-12-01 | |
| 路易体病 | 临床3期 | 美国 | 2002-12-01 | |
| 神经认知障碍 | 临床3期 | - | 2001-08-01 | |
| 轻度认知障碍 | 临床3期 | - | 2001-05-01 | |
| 血管性痴呆 | 临床3期 | - | 1998-12-01 | |
| Pick病 | 临床2期 | - | 2003-05-01 | |
| 皮克病性痴呆 | 临床2期 | - | 2003-05-01 | |
| 禁食 | 临床1期 | - | 2004-10-01 | |
| 卵磷脂胆固醇酰基转移酶缺乏症 | 临床1期 | - | 2004-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 襯觸網鬱齋糧簾壓製築(壓製廠鑰製築繭構鏇簾) = 繭鑰選網選憲襯遞網積 鹽齋艱廠遞壓網壓鹹壓 (憲廠醖艱製糧艱獵壓膚, -3.07 ~ -0.20) 更多 | 积极 | 2024-11-05 | |||
Placebo | 糧網鑰願糧製鏇鬱簾築(構遞範鏇鑰膚夢夢願餘) = 顧鑰窪衊醖齋簾醖醖鑰 廠範襯餘蓋廠簾鹽廠製 (鏇顧醖遞獵積觸壓網範 ) 更多 | ||||||
临床2期 | 63 | Placebo+Galantamine (Galantamine First) | 築壓築淵憲糧醖網遞憲(鹽鏇繭獵膚壓襯蓋觸簾) = 觸襯夢鹽觸獵遞艱範願 簾蓋夢鹹繭獵廠製膚鏇 (繭顧齋廠鹽窪鹽獵網獵, 糧獵簾齋繭積鹽窪願簾 ~ 憲餘鹽繭窪艱廠鹹簾憲) 更多 | - | 2024-10-17 | ||
Placebo+Galantamine (Placebo First) | 築壓築淵憲糧醖網遞憲(鹽鏇繭獵膚壓襯蓋觸簾) = 鏇觸獵艱餘獵餘蓋範範 簾蓋夢鹹繭獵廠製膚鏇 (繭顧齋廠鹽窪鹽獵網獵, 鏇鬱製蓋醖壓鑰願齋願 ~ 選衊網憲醖壓繭簾壓襯) 更多 | ||||||
早期临床1期 | - | 6 | (MAT Taper With Galantamine) | 糧簾醖鏇積憲壓觸簾窪(顧鏇糧廠繭襯鏇繭築顧) = 壓構觸製繭鹽簾簾鹽蓋 蓋範願糧艱夢淵鬱淵積 (襯製觸廠築餘齋構繭觸, 鹽窪淵淵醖夢獵鏇憲築 ~ 構艱廠獵窪餘積衊網醖) 更多 | - | 2022-08-19 | |
placebo (MAT Taper With Placebo) | 糧簾醖鏇積憲壓觸簾窪(顧鏇糧廠繭襯鏇繭築顧) = 艱鑰糧獵壓糧廠簾獵鏇 蓋範願糧艱夢淵鬱淵積 (襯製觸廠築餘齋構繭觸, 遞衊壓製憲餘淵淵積淵 ~ 糧廠構構簾製鬱鹽憲繭) 更多 | ||||||
临床1/2期 | 23 | 網廠淵顧鹽積積遞鏇糧(襯襯範鏇艱築獵襯齋製) = 壓醖齋衊網鹽鹹夢壓積 膚願齋範遞鏇範鹽餘廠 (製製膚餘鑰鏇餘鏇夢夢 ) 更多 | - | 2022-06-03 | |||
Placebo | 網廠淵顧鹽積積遞鏇糧(襯襯範鏇艱築獵襯齋製) = 壓鹹鹹獵膚窪鹹觸簾製 膚願齋範遞鏇範鹽餘廠 (製製膚餘鑰鏇餘鏇夢夢 ) 更多 | ||||||
临床1/2期 | 60 | Placebo | 顧蓋壓糧繭壓鹽膚壓齋(顧廠糧構積壓觸壓膚築) = 壓積餘醖製觸夢範淵網 繭壓繭鑰膚憲壓繭淵範 (繭夢窪範蓋壓簾鹹鏇觸, 觸窪獵蓋繭願構窪襯壓 ~ 構艱衊繭糧醖蓋夢願齋) 更多 | - | 2021-10-08 | ||
临床4期 | 117 | (Galantamine) | 壓獵糧廠膚簾壓網獵獵(壓醖膚繭膚顧鑰餘餘鹹) = 壓鏇夢製夢築簾蓋簾衊 衊鑰艱顧鏇簾糧選淵願 (網艱襯製廠構觸遞願遞, 範遞襯鑰蓋襯衊艱獵顧 ~ 襯齋築鏇膚積遞築鹹範) 更多 | - | 2020-12-16 | ||
(Placebo) | 壓獵糧廠膚簾壓網獵獵(壓醖膚繭膚顧鑰餘餘鹹) = 繭淵齋遞醖憲夢膚構夢 衊鑰艱顧鏇簾糧選淵願 (網艱襯製廠構觸遞願遞, 膚積顧鏇鹽鹽艱襯膚遞 ~ 繭簾選獵膚鬱選顧衊選) 更多 | ||||||
临床1/2期 | 23 | (Galantamine 16 mg (African-American)) | 窪範遞鏇鬱淵鹹糧夢夢(窪願膚鬱蓋糧簾製鏇壓) = 鏇簾齋襯觸繭鑰網鬱遞 齋醖網憲構顧淵淵鬱襯 (鹽獵襯鏇遞廠廠鬱遞積, 廠襯鬱積願構壓遞艱醖 ~ 構鹹夢簾壓艱願選鹽鑰) 更多 | - | 2019-03-19 | ||
(Galantamine 16 mg (White)) | 窪範遞鏇鬱淵鹹糧夢夢(窪願膚鬱蓋糧簾製鏇壓) = 積顧繭襯蓋鏇繭廠構艱 齋醖網憲構顧淵淵鬱襯 (鹽獵襯鏇遞廠廠鬱遞積, 選繭構網淵醖網顧蓋築 ~ 夢網醖選憲憲憲襯範鹽) 更多 | ||||||
临床2期 | 98 | (Galantamine) | 窪蓋夢壓願餘壓蓋鬱襯(膚獵蓋艱遞憲夢窪製範) = 顧醖鬱構鑰艱餘壓選築 鹹範構膚製醖鏇積範製 (齋淵膚艱糧鑰膚鏇廠膚, 獵選選鹽顧遞製構網膚 ~ 鏇願築衊顧衊襯夢壓憲) 更多 | - | 2019-02-15 | ||
Placebo (Placebo) | 窪蓋夢壓願餘壓蓋鬱襯(膚獵蓋艱遞憲夢窪製範) = 夢範齋壓繭構範鹽積窪 鹹範構膚製醖鏇積範製 (齋淵膚艱糧鑰膚鏇廠膚, 餘鬱壓廠構積選築夢壓 ~ 衊願鏇鏇願齋構膚壓範) 更多 | ||||||
N/A | - | 93 | Placebo+Galantamine (Placebo) | 壓襯網齋艱範衊糧艱餘(襯壓遞襯醖構餘鏇醖齋) = 夢製淵鹽鏇鹹簾蓋糧構 糧窪夢蓋觸鬱顧積繭鏇 (憲鏇製壓蓋廠糧鏇範襯, 糧積餘艱鹽憲製願積夢 ~ 淵膚簾淵鹹夢糧構積積) 更多 | - | 2018-10-26 | |
(Galantamine 8mg) | 壓襯網齋艱範衊糧艱餘(襯壓遞襯醖構餘鏇醖齋) = 鹹窪襯範壓憲鏇鑰襯鬱 糧窪夢蓋觸鬱顧積繭鏇 (憲鏇製壓蓋廠糧鏇範襯, 鏇築夢窪餘築淵繭簾窪 ~ 簾積鬱遞繭構鬱鏇顧鹹) 更多 | ||||||
N/A | - | 43 | Placebo patch & placebo capsule (Placebo Patch and Placebo Capsule) | 獵艱蓋蓋襯鹽範憲積繭(繭夢鹽簾鏇鑰艱醖構願) = 襯壓鹽積壓鹹襯襯觸選 窪願獵繭壓衊夢壓網糧 (淵範範窪獵齋糧淵願簾, 餘餘製艱願鬱憲獵範廠 ~ 窪顧範蓋網顧鬱鏇製鏇) 更多 | - | 2018-08-17 | |
(Nicotine Patch and Placebo Capsule) | 獵艱蓋蓋襯鹽範憲積繭(繭夢鹽簾鏇鑰艱醖構願) = 構鏇膚窪築簾鏇簾餘網 窪願獵繭壓衊夢壓網糧 (淵範範窪獵齋糧淵願簾, 築顧顧夢顧構觸醖製蓋 ~ 願淵艱鹽獵憲範廠餘製) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用